Page last updated: 2024-08-24

ferric citrate and Disease Exacerbation

ferric citrate has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Block, GA; Chertow, GM; Fishbane, S; Pergola, PE; Rodriguez, M; Shemesh, S; Smits, G; Wolf, M	1
Vaziri, ND	1
Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F	1

Reviews

2 review(s) available for ferric citrate and Disease Exacerbation

Article	Year
Safety Issues in Iron Treatment in CKD. Seminars in nephrology, 2016, Volume: 36, Issue:2 Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Progression; Ferric Compounds; Hematinics; Humans; Iron Compounds; Iron Overload; Kidney Failure, Chronic; Oxidative Stress; Reactive Oxygen Species; Renal Dialysis; Renal Insufficiency, Chronic	2016
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25 Suppl 2 Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors	2005

Article

Year

Safety Issues in Iron Treatment in CKD.

Seminars in nephrology, 2016, Volume: 36, Issue:2

Topics: Anemia, Iron-Deficiency; Cardiovascular Diseases; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Progression; Ferric Compounds; Hematinics; Humans; Iron Compounds; Iron Overload; Kidney Failure, Chronic; Oxidative Stress; Reactive Oxygen Species; Renal Dialysis; Renal Insufficiency, Chronic

2016

[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25 Suppl 2

Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors

2005

Trials

1 trial(s) available for ferric citrate and Disease Exacerbation

Article	Year
A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:5 Topics: Aged; Anemia, Iron-Deficiency; Disease Progression; Double-Blind Method; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hematinics; Humans; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic	2015

Article

Year

A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 65, Issue:5

Topics: Aged; Anemia, Iron-Deficiency; Disease Progression; Double-Blind Method; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hematinics; Humans; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic

2015